Immune cell-based screening assay for response to anticancer agents: applications in pharmacogenomics

Area of Science:

• Immunology
• Pharmacology
• Genetics

Background:

• Interpatient variability in chemotherapy response is linked to genetic factors.
• A novel drug screening platform using genetically diverse mouse strains was developed.
• The platform examines differences in immune cell viability after cytotoxic insult.

Purpose of the Study:

• To investigate interstrain differences in immune cell viability following chemotherapeutic exposure.
• To compare the toxicity of targeted agents (BEZ-235, selumetinib) versus conventional agents (doxorubicin, idarubicin).

Main Methods:

• Splenocytes from 36 mouse strains were incubated with various chemotherapeutic agents.
• Cells were analyzed via flow cytometry to assess viability and phenotypes.
• Dose-response curves were generated to quantify drug effects.

Main Results:

• Significant interstrain variations in immune cell viability were observed.
• Targeted agents (BEZ-235, selumetinib) showed lower immune cell toxicity compared to anthracyclines.
• Higher heritability of immune cell viability was found for anthracyclines, suggesting suitability for genetic analysis.

Conclusions:

• The developed platform identifies cell lines with variable drug sensitivity.
• Robust cellular response endpoints were established for identifying candidate genes.
• This approach provides a foundation for future validation of cellular toxicity pathways in human studies.